| Literature DB >> 30819119 |
Hong Ji1, Le Lu1, Jingjing Huang1, Yang Liu2, Binchao Zhang3, Hui Tang1, Dangze Sun1, Yafei Zhang1, Hao Shang1, Yiming Li1, Hongwei Lu4.
Abstract
BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers worldwide, and genetic variations exert distinct roles in its pathogenesis. Single nucleotide polymorphisms (SNPs) in interleukin 1 alpha (IL1A) were reported to be correlated to the susceptibility of diverse cancers. The aim of this study was to assess the association of IL1A SNPs with the risk of colorectal cancer in a Chinese Han population.Entities:
Keywords: Chinese Han population; Colorectal cancer; IL1A; Single-nucleotide polymorphisms; Stratification analysis
Mesh:
Substances:
Year: 2019 PMID: 30819119 PMCID: PMC6394039 DOI: 10.1186/s12885-019-5395-9
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Basic information and allele frequencies of the five selected SNPs
| SNP_ID | Gene | Chromosome | Position | Allele | Minor allele frequency | HWE | OR (95% CI) |
| |
|---|---|---|---|---|---|---|---|---|---|
| Case | Control | ||||||||
| rs3783550 | IL1A | 2q13 | 113,532,885 | T/G | 0.358 | 0.326 | 0.399 | 1.15 (0.91–1.45) | 0.222 |
| rs3783546 | IL1A | 2q13 | 113,534,830 | C/G | 0.353 | 0.325 | 0.458 | 1.13 (0.90–1.42) | 0.296 |
| rs2856838 | IL1A | 2q13 | 113,539,972 | A/G | 0.256 | 0.247 | 0.319 | 1.04 (0.81–1.35) | 0.716 |
| rs1609682 | IL1A | 2q13 | 113,540,205 | T/G | 0.354 | 0.327 | 0.398 | 1.12 (0.90–1.42) | 0.298 |
| rs3783521 | IL1A | 2q13 | 113,543,577 | G/A | 0.356 | 0.326 | 0.399 | 1.14 (0.91–1.44) | 0.252 |
SNP Single nucleotide polymorphism, HWE Hardy-Weinberg equilibrium, OR Odds ratio, 95% CI, 95% confidence interval
HWE p-value obtained from Fisher’s exact test (p > 0.05)
pa values were calculated from Pearson’s χ2 test regarding to the allele distribution frequencies among CRC patients and healthy controls
p < 0.05 indicates SNP with statistical significance
Genetic model analyses of IL1A SNPs and the risk of CRC
| SNP_ID | Genotypes | Controls, n (%) | Patients, n (%) | Without adjustment | With adjustment | ||
|---|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| ||||
| rs3783550 | |||||||
| G/G | 206 (44.5%) | 103 (41.7%) | 1.00 | 1.00 | |||
| Codominant | G/T | 212 (45.8%) | 111 (44.9%) | 1.05 (0.75–1.46) | 0.330 | 1.01 (0.72–1.44) | 0.310 |
| T/T | 45 (9.7%) | 33 (13.4%) | 1.47 (0.88–2.44) | 1.49 (0.88–2.52) | |||
| Dominant (ref: G/G) | G/T-T/T | 257 (55.5%) | 144 (58.3%) | 1.12 (0.82–1.53) | 0.470 | 1.10 (0.79–1.52) | 0.580 |
| Recessive (ref: G/G + G/T) | T/T | 45 (9.7%) | 33 (13.4%) | 1.43 (0.89–2.31) | 0.140 | 1.48 (0.90–2.43) | 0.130 |
| rs3783546 | |||||||
| G/G | 206 (44.7%) | 104 (41.9%) | 1.00 | 1.00 | |||
| Codominant | G/C | 210 (45.5%) | 113 (45.6%) | 1.07 (0.77–1.48) | 0.500 | 1.02 (0.73–1.45) | 0.500 |
| C/C | 45 (9.8%) | 31 (12.5%) | 1.36 (0.82–2.28) | 1.37 (0.80–2.34) | |||
| Dominant (ref: G/G) | G/C-C/C | 255 (55.3%) | 144 (58.1%) | 1.12 (0.82–1.53) | 0.480 | 1.09 (0.78–1.51) | 0.620 |
| Recessive (ref: G/G + G/C) | C/C | 45 (9.8%) | 31 (12.5%) | 1.32 (0.81–2.15) | 0.270 | 1.35 (0.82–2.24) | 0.240 |
| rs2856838 | |||||||
| G/G | 257 (55.8%) | 143 (57.7%) | 1.00 | 1.00 | |||
| Codominant | G/A | 180 (39%) | 83 (33.5%) | 0.83 (0.60–1.15) | 0.096 | 0.83 (0.58–1.17) | 0.063 |
| A/A | 24 (5.2%) | 22 (8.9%) | 1.65 (0.89–3.04) | 1.84 (0.96–3.50) | |||
| Dominant (ref:G/G) | G/A-A/A | 204 (44.2%) | 105 (42.3%) | 0.93 (0.68–1.26) | 0.620 | 0.94 (0.68–1.31) | 0.720 |
| Recessive (ref: G/G + G/A) | A/A | 24 (5.2%) | 22 (8.9%) | 1.77 (0.97–3.23) | 0.064 |
|
|
| rs1609682 | |||||||
| G/G | 205 (44.4%) | 105 (42.5%) | 1.00 | 1.00 | |||
| Codominant | G/T | 212 (45.9%) | 109 (44.1%) | 1.00 (0.72–1.40) | 0.350 | 0.97 (0.68–1.37) | 0.310 |
| T/T | 45 (9.7%) | 33 (13.4%) | 1.43 (0.86–2.38) | 1.45 (0.85–2.45) | |||
| Dominant (ref: G/G) | G/T-T/T | 257 (55.6%) | 142 (57.5%) | 1.08 (0.79–1.47) | 0.630 | 1.05 (0.76–1.46) | 0.770 |
| Recessive (ref: G/G + G/T) | T/T | 45 (9.7%) | 33 (13.4%) | 1.43 (0.89–2.31) | 0.150 | 1.47 (0.89–2.42) | 0.130 |
| rs3783521 | |||||||
| A/A | 206 (44.5%) | 103 (41.7%) | 1.00 | 1.00 | |||
| Codominant | G/A | 212 (45.8%) | 112 (45.3%) | 1.06 (0.76–1.47) | 0.400 | 1.02 (0.72–1.44) | 0.410 |
| G/G | 45 (9.7%) | 32 (13.0%) | 1.42 (0.85–2.37) | 1.42 (0.84–2.42) | |||
| Dominant (ref: A/A) | G/A-G/G | 257 (55.5%) | 144 (58.3%) | 1.12 (0.82–1.53) | 0.470 | 1.09 (0.79–1.51) | 0.610 |
| Recessive (ref: A/A + G/A) | G/G | 45 (9.7%) | 32 (13.0%) | 1.38 (0.85–2.24) | 0.190 | 1.41 (0.86–2.33) | 0.180 |
SNP Single nucleotide polymorphism, OR Odds ratio; 95% CI: 95% confidence interval
pa-values were calculated by logistic regression analysis with the comparison between CRC patients and healthy controls
pb-values were calculated by logistic regression analysis with adjustments for age and gender
Bold italics indicates the SNP with statistical significance (p < 0.05)
Association of the selected SNPs in IL1A with CRC risk after stratified analysis by gender
| SNP_ID | Genotypes | Male | OR (95% CI) |
| Female | OR (95% CI) |
| ||
|---|---|---|---|---|---|---|---|---|---|
| Controls, n(%) | Patients, n(%) | Controls, n(%) | Patients, n(%) | ||||||
| rs3783550 | |||||||||
| G/G | 113 (42.6%) | 62 (43.7%) | 1.00 | 93 (47.0%) | 41 (39.0%) | 1.00 | |||
| Codominant | G/T | 123 (46.4%) | 63 (44.4%) | 0.85 (0.53–1.38) | 0.800 | 89 (45.0%) | 48 (45.7%) | 1.22 (0.73–2.04) | 0.096 |
| T/T | 29 (10.9%) | 17 (12.0%) | 0.96 (0.47–1.98) | 16 (8.1%) | 16 (15.2%) | 2.41 (1.09–5.34) | |||
| Dominant (ref: G/G) | G/T-T/T | 152 (57.4%) | 80 (56.3%) | 0.88 (0.56–1.38) | 0.560 | 105 (53.0%) | 64 (61.0%) | 1.40 (0.86–2.27) | 0.180 |
| Recessive (ref: G/G + G/T) | T/T | 29 (10.9%) | 17 (12.0%) | 1.05 (0.53–2.06) | 0.900 | 16 (8.1%) | 16 (15.2%) |
|
|
| rs3783546 | |||||||||
| G/G | 113 (42.8%) | 62 (43.4%) | 1.00 | 93 (47.2%) | 42 (40.0%) | 1.00 | |||
| Codominant | G/C | 122 (46.2%) | 65 (45.5%) | 0.87 (0.54–1.40) | 0.850 | 88 (44.7%) | 48 (45.7%) | 1.21 (0.72–2.01) | 0.170 |
| C/C | 29 (11.0%) | 16 (11.2%) | 0.92 (0.44–1.90) | 16 (8.1%) | 15 (14.3%) | 2.18 (0.97–4.85) | |||
| Dominant (ref: G/G) | G/C-C/C | 151 (57.2%) | 81 (56.6%) | 0.88 (0.56–1.38) | 0.580 | 104 (52.8%) | 63 (60.0%) | 1.35 (0.83–2.20) | 0.220 |
| Recessive (ref: G/G + G/C) | C/C | 29 (11.0%) | 16 (11.2%) | 0.98 (0.49–1.95) | 0.960 | 16 (8.1%) | 15 (14.3%) | 1.98 (0.93–4.21) | 0.080 |
| rs2856838 | |||||||||
| G/G | 142 (54.0%) | 88 (61.5%) | 1.00 | 115 (58.1%) | 55 (52.4%) | 1.00 | |||
| Codominant | G/A | 109 (41.4%) | 47 (32.9%) | 0.68 (0.42–1.10) | 0.260 | 71 (35.9%) | 36 (34.3%) | 1.06 (0.63–1.77) | 0.078 |
| A/A | 12 (4.6%) | 8 (5.6%) | 1.07 (0.39–2.94) | 12 (6.1%) | 14 (13.3%) | 2.63 (1.13–6.15) | |||
| Dominant (ref: G/G) | G/A-A/A | 121 (46.0%) | 55 (38.5%) | 0.72 (0.46–1.14) | 0.160 | 83 (41.9%) | 50 (47.6%) | 1.27 (0.79–2.06) | 0.330 |
| Recessive (ref: G/G + G/A) | A/A | 12 (4.6%) | 8 (5.6%) | 1.24 (0.46–3.36) | 0.670 | 12 (6.1%) | 14 (13.3%) |
|
|
| rs1609682 | |||||||||
| G/G | 113 (42.6%) | 64 (44.8%) | 1.00 | 92 (46.7%) | 41 (39.4%) | 1.00 | |||
| Codominant | G/T | 123 (46.4%) | 62 (43.4%) | 0.81 (0.50–1.30) | 0.670 | 89 (45.2%) | 47 (45.2%) | 1.18 (0.70–1.98) | 0.100 |
| T/T | 29 (10.9%) | 17 (11.9%) | 0.93 (0.45–1.90) | 16 (8.1%) | 16 (15.4%) | 2.39 (1.08–5.31) | |||
| Dominant (ref: G/G) | G/T-T/T | 152 (57.4%) | 79 (55.2%) | 0.83 (0.53–1.31) | 0.420 | 105 (53.3%) | 63 (60.6%) | 1.36 (0.83–2.21) | 0.220 |
| Recessive (ref: G/G + G/T) | T/T | 29 (10.9%) | 17 (11.9%) | 1.03 (0.53–2.04) | 0.920 | 16 (8.1%) | 16 (15.4%) |
|
|
| rs3783521 | |||||||||
| A/A | 113 (42.6%) | 62 (43.7%) | 1.00 | 93 (47.0%) | 41 (39.0%) | 1.00 | |||
| Codominant | G/A | 123 (46.4%) | 64 (45.1%) | 0.86 (0.53–1.38) | 0.820 | 89 (45.0%) | 48 (45.7%) | 1.22 (0.73–2.04) | 0.110 |
| G/G | 29 (10.9%) | 16 (11.3%) | 0.92 (0.44–1.90) | 16 (8.1%) | 16 (15.2%) | 2.36 (1.07–5.22) | |||
| Dominant (ref: A/A) | G/A-G/G | 152 (57.4%) | 80 (56.3%) | 0.87 (0.55–1.37) | 0.540 | 105 (53.0%) | 64 (61.0%) | 1.39 (0.86–2.26) | 0.180 |
| Recessive (ref: A/A + G/A) | G/G | 29 (10.9%) | 16 (11.3%) | 0.99 (0.50–1.97) | 0.980 | 16 (8.1%) | 16 (15.2%) |
|
|
SNP Single nucleotide polymorphism, OR Odds ratio; 95% CI: 95% confidence interval
pa-values were calculated by logistic regression analysis with adjustment for age in males
pb-values were calculated by logistic regression analysis with adjustment for age in females
Bold italics indicates the SNP with statistical significance (p < 0.05)
IL1A haplotype frequencies and the association with CRC risk
| Block | Haplotype | Freq (case) | Freq (control) | OR (95% CI) |
|
|---|---|---|---|---|---|
| rs3783550/rs3783546/rs2856838 | GGGGA | 0.640 | 0.674 | 1.00 | |
| TCATG | 0.250 | 0.249 | 1.07 (0.83–1.39) | 0.600 | |
| TCGTG | 0.100 | 0.077 | 1.33 (0.90–1.97) | 0.150 |
OR Odds ratio; 95% CI: 95% confidence interval
pa-values were obtained after adjustments for gender and age with the comparison between CRC patients and healthy controls
Fig. 1Haplotype block map formed by the SNPs in IL1A gene. Haplotype block are formed by rs3783550, rs3783546, rs2856838, rs1609682 and rs3783521 at 10 kb totally